Eimear E Kenny, PhD
- DIRECTOR, INSTITUTE FOR GENOMIC HEALTH
- ASSOCIATE PROFESSOR | Genetics and Genomic Sciences
- ASSOCIATE PROFESSOR | Medicine, General Internal Medicine
Research Topics:Genetics, Genomics
Dr. Eimear Kenny, PhD, is Founding Director of the Institute for Genomic Health, and Associate Professor of Medicine and Genetics at Mount Sinai. She lead research at the interface of genomics, medicine, and computer science. Her research spans a number of different fields, including population and statistical genetics; computational and machine-learning approaches for genomics; biobank- and cohort-based research on monogenic disorders and common diseases; polygenic risk for human diseases and precision medicine. Her goal is to lead a new paradigms for genomic research and to enable genomic medicine on a global scale. She is Principal Investigator in six large international programs focused on genomic research, medicine and health, and is in the top 20 NIH-funded genomics researchers in the US. She is a scientific advisor to many genomic and genomic medicine initiatives in government, non-profit and industry arenas. She has published over 90 papers in leading journals like Science, Nature, Nature Genetics, NEJM, with over 13,000 citations, and her work has been featured by many media outlets including the New York Times.
She has a BA in Biochemistry from Trinity College Dublin, a PhD in computational genomics from Rockefeller University, and did her postdoctoral training in population genetics at Stanford University.
Multi-Disciplinary Training AreaGenetics and Data Science [GDS]
BSc, Trinity College Dublin
MSc, University of Leeds
PhD, Rockefeller University
Post-doc, Stanford University
Dr. Kenny is Founding Director of the Center for Genomic Health (CGH). She leads a multidisciplinary team of geneticists, computer scientists, clinicians, and other medical professionals, working on problems at the interface of computational genomics and medicine. Her goal is to bring state-of-the-art genomic technology and data science to improve clinical care, particularly in diverse and medically underserved populations. Current activities in CGH include genomic discovery in biobanks and disease cohorts using databases of hundreds of thousands of human genomes; a large clinical trial to examine how complex genomic information is communicated in health systems; and a program to offer genomic screening in clinical care to enable early detection and prevention of diseases, such as breast cancer, diabetes and heart disease. She is scientific advisor to multiple genomic medicine initiatives in non-profit, government and industry arenas.